James P. Stevenson, MD
Ultima Vez Modificado: 1 de noviembre del 2001
Dear OncoLink "Ask the Experts,"
I was wondering what you could tell me about Mucinous Adenocarcinoma of the colon and a new treatment using CPT11-5FU-LUKOVORAN?
James P. Stevenson, MD, Assistant Professor of Medicine in the Hematology/Oncology Division of the University of Pennsylvania School of Medicine, responds:
Mucinous adenocarcinoma is a term that describes the way this colon cancer looks under a microscope. We treat it the same way as any other colon cancer. The CPT11/5-FU/leucovorin combination is now the standard front-line treatment for metastatic colon cancer. It combines drugs that have been known to be active against colon cancer. Multiple studies have shown that by combining them, better tumor response rates (about 50%) and survival of patients can be expected than when they are used alone.
The treatments are given once a week for 4 consecutive weeks followed by a 2-week break period with no treatment. These 6-week cycles can be repeated if there are signs of improvement. There are randomized trials looking at adding newer drugs to this combination, such as anti-VEGF and celecoxib that may be available in your area, and are being studied here at Penn. You might ask your oncologist if you may be eligible for any of these studies.Imprima English
Nov 27, 2014 - In patients with synchronous stage IV colorectal cancer who receive up-front modern combination chemotherapy, immediate colon surgery to remove the primary tumor is seldom necessary, according to research presented at the annual meeting of the American Society of Clinical Oncology, held from May 29 to June 2 in Orlando, Fla. These findings accompanied several other studies presented at the conference focusing on treatment of gastrointestinal cancers.
Nov 27, 2014
Jan 20, 2012